Epstein-Barr virus and human papillomavirus serum antibodies define the viral status of nasopharyngeal carcinoma in a low endemic country.
Adult
Aged
Antibodies, Viral
/ blood
Case-Control Studies
Epstein-Barr Virus Infections
/ diagnosis
Female
Herpesvirus 4, Human
/ immunology
Humans
Immunoglobulin A
/ blood
Immunoglobulin G
/ blood
Male
Middle Aged
Nasopharyngeal Carcinoma
/ immunology
Nasopharyngeal Neoplasms
/ immunology
Papillomaviridae
/ immunology
Papillomavirus Infections
/ diagnosis
Epstein-Barr virus
human papillomavirus
multiplex serology
nasopharyngeal carcinoma
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 07 2020
15 07 2020
Historique:
received:
26
11
2019
revised:
27
02
2020
accepted:
24
03
2020
pubmed:
13
4
2020
medline:
9
3
2021
entrez:
13
4
2020
Statut:
ppublish
Résumé
Epstein-Barr virus (EBV) causes nasopharyngeal carcinoma (NPC) in endemic regions, where almost every tumor is EBV-positive. In Western populations, NPC is rare, and human papillomavirus infection (HPV) has been suggested as another viral cause. We validated multiplex serology with molecular tumor markers, to define EBV-positive, HPV-positive and EBV-/HPV-negative NPCs in the United Kingdom, and analyzed survival differences between those groups. Sera from NPC cases (n = 98) and age- and sex-matched controls (n = 142) from the Head and Neck 5000 clinical cohort study were analyzed. IgA and IgG serum antibodies against 13 EBV antigens were measured and compared with EBER in situ hybridization (EBER-ISH) data of 41 NPC tumors (29 EBER-ISH positive, 12 negative). IgG antibodies to EBV LF2 correctly diagnosed EBV-positive NPCs in 28 of 29 cases, while all EBER-ISH negative NPCs were seronegative to LF2 IgG (specificity = 100%, sensitivity = 97%). HPV early antigen serology was compared to HPV molecular markers (p16 expression, HPV DNA and RNA) available for 41 NPCs (13 positive, 28 negative). Serology matched molecular HPV markers in all but one case (specificity = 100%, sensitivity = 92%). EBV and HPV infections were mutually exclusive. Overall, 67% of the analyzed NPCs were defined as EBV-positive, 18% as HPV-positive and 14% as EBV/HPV-negative. There was no statistical evidence of a difference in survival between the three groups. These data provide evidence that both, EBV-positive and HPV-positive NPCs are present in a low incidence country, and that EBV and HPV serum antibodies correlate with the viral status of the tumor.
Substances chimiques
Antibodies, Viral
0
Immunoglobulin A
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
461-471Subventions
Organisme : Cancer Research UK
ID : C18281/A19169
Pays : United Kingdom
Organisme : Department of Health
ID : RP-PG-0707-10034
Pays : United Kingdom
Informations de copyright
© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-E386.
Chang ET, Adami H-O. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:1765-1777.
Old LJ, Boyse EA, Oettgen HF, et al. Precipitating antibody in human serum to an antigen present in cultured Burkitt's lymphoma cells. Proc Natl Acad Sci USA. 1966;56:1699-1704.
Lanier AP, Bornkamm GW, Henle W, et al. Association of Epstein-Barr virus with nasopharyngeal carcinoma in Alaskan native patients: serum antibodies and tissue EBNA and DNA. Int J Cancer. 1981;28:301-305.
Lin TM, Yang CS, Chiou JF, et al. Antibodies to Epstein-Barr virus capsid antigen and early antigen in nasopharyngeal carcinoma and comparison groups. Am J Epidemiol. 1977;106:336-339.
Pearson GR, Weiland LH, Neel HB 3rd, et al. Application of Epstein-Barr virus (EBV) serology to the diagnosis of north American nasopharyngeal carcinoma. Cancer. 1983;51:260-268.
Cao SM, Liu Z, Jia WH, et al. Fluctuations of Epstein-Barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PLoS One. 2011;6:e19100.
Chien YC, Chen JY, Liu MY, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med. 2001;345:1877-1882.
Coghill AE, Pfeiffer RM, Proietti C, et al. Identification of a novel, EBV-based antibody risk stratification signature for early detection of nasopharyngeal carcinoma in Taiwan. Clin Cancer Res. 2018;24:1305-1314.
Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol. 2002;12:431-441.
Xue W-Q, Qin H-D, Ruan H-L, Shugart YY, Jia W-H. Quantitative Association of Tobacco Smoking with the risk of nasopharyngeal carcinoma: a comprehensive meta-analysis of studies conducted between 1979 and 2011. Am J Epidemiol. 2013;178:325-338.
Robinson M, Suh Y-E, Paleri V, et al. Oncogenic human papillomavirus-associated nasopharyngeal carcinoma: an observational study of correlation with ethnicity, histological subtype and outcome in a UKpopulation. Infect Agents Cancer. 2013;8:30.
Dogan S, Hedberg ML, Ferris RL, Rath TJ, Assaad AM, Chiosea SI. Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population. Head Neck. 2014;36:511-516.
Singhi AD, Califano J, Westra WH. High-risk human papillomavirus in nasopharyngeal carcinoma. Head Neck. 2012;34:213-218.
Ruuskanen M, Irjala H, Minn H, et al. Epstein-Barr virus and human papillomaviruses as favorable prognostic factors in nasopharyngeal carcinoma: a nationwide study in Finland. Head Neck. 2019;41:349-357.
D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:1944-1956.
Kreimer AR, Johansson M, Waterboer T, et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol. 2013;31:2708-2715.
Castellsagué X, Alemany L, Quer M, et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst. 2016;108:djv403.
Ngan H-L, Wang L, Lo K-W, Lui VWY. Genomic landscapes of EBV-associated nasopharyngeal carcinoma vs. HPV-associated head and neck cancer. Cancer. 2018;10:210.
Kreimer AR, Johansson M, Yanik EL, et al. Kinetics of the human papillomavirus type 16 E6 antibody response prior to oropharyngeal cancer. J Natl Cancer Inst. 2017;109:djx005.
Holzinger D, Wichmann G, Baboci L, et al. Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma. Int J Cancer. 2017;140:2748-2757.
Dahlstrom KR, Anderson KS, Cheng JN, et al. HPV serum antibodies as predictors of survival and disease progression in patients with HPV-positive squamous cell carcinoma of the oropharynx. Clin Cancer Res. 2015;21:2861-2869.
Stenmark MH, McHugh JB, Schipper M, et al. Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int J Radiat Oncol Biol Phys. 2014;88:580-588.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
Ness AR, Waylen A, Hurley K, et al. Establishing a large prospective clinical cohort in people with head and neck cancer as a biomedical resource: head and neck 5000. BMC Cancer. 2014;14:973.
Ness AR, Waylen A, Hurley K, et al. Recruitment, response rates and characteristics of 5511 people enrolled in a prospective clinical cohort study: head and neck 5000. Clin Otolaryngol. 2016;41:804-809.
Muderris T, Rota S, Muderris T, Inal E, Fidan I. Does Epstein-Barr virus infection have an influence on the development of laryngeal carcinoma? Detection of EBV by real-time polymerase chain reaction in tumour tissues of patients with laryngeal carcinoma. Braz J Otorhinolaryngol. 2013;79:418-423.
Ambinder RF, Mann RB. Epstein-Barr-encoded RNA in situ hybridization: diagnostic applications. Hum Pathol. 1994;25:602-605.
Halec G, Schmitt M, Dondog B, et al. Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer. Int J Cancer. 2013;132:63-71.
Schmitt M, Bravo IG, Snijders PJF, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol. 2006;44:504-512.
Schmitt M, Dondog B, Waterboer T, Pawlita M. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol. 2008;46:1050-1059.
Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem. 2005;51:1845-1853.
Waterboer T, Sehr P, Pawlita M. Suppression of non-specific binding in serological Luminex assays. J Immunol Methods. 2006;309:200-204.
Brenner N, Mentzer AJ, Butt J, et al. Validation of multiplex serology detecting human herpesviruses 1-5. PLoS One. 2018;13:e0209379.
Beynon RA, Lang S, Schimansky S, et al. Tobacco smoking and alcohol drinking at diagnosis of head and neck cancer and all-cause mortality: results from head and neck 5000, a prospective observational cohort of people with head and neck cancer. Int J Cancer. 2018;143:1114-1127.
McLennan D, Noble M, Davies J, Garratt E. The English Indices of Deprivation 2010. Government DfCaL, 2011. https://www.gov.uk/government/statistics/english-indices-of-deprivation-2010 (accessed September 11, 2019).
van Grunsven WMJ, Spaan WJM, Middeldorp JM. Localization and diagnostic application of Immunodominant domains of the BFRF3-encoded Epstein-Barr virus capsid protein. J Infect Dis. 1994;170:13-19.
Middeldorp JM. Epstein-Barr virus-specific humoral immune responses in health and disease. Curr Top Microbiol Immunol. 2015;391:289-323.
Fachiroh J, Paramita DK, Hariwiyanto B, et al. Single-assay combination of Epstein-Barr virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. J Clin Microbiol. 2006;44:1459-1467.
Calderwood MA, Venkatesan K, Xing L, et al. Epstein-Barr virus and virus human protein interaction maps. Proc Natl Acad Sci USA. 2007;104:7606-7611.
Calderwood MA, Holthaus AM, Johannsen E. The Epstein-Barr virus LF2 protein inhibits viral replication. J Virol. 2008;82:8509-8519.
Tierney RJ, Shannon-Lowe CD, Fitzsimmons L, Bell AI, Rowe M. Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA. Virology. 2015;474:117-130.
Lang Kuhs KA, Pawlita M, Gibson SP, et al. Characterization of human papillomavirus antibodies in individuals with head and neck cancer. Cancer Epidemiol. 2016;42:46-52.
Lin Z, Khong B, Kwok S, et al. Human papillomavirus 16 detected in nasopharyngeal carcinomas in white Americans but not in endemic southern Chinese patients. Head Neck. 2014;36:709-714.
Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11:781-789.
Stenmark MH, McHugh JB, Schipper M, et al. High frequency of HPV-associated nasopharyngeal carcinoma (NPC) in North American patients: association with poor prognosis. Int J Radiat Oncol Biol Phys. 2013;87:S79-S80.
Schache AG, Powell NG, Cuschieri KS, et al. HPV-related oropharynx cancer in the United Kingdom: an evolution in the understanding of disease etiology. Cancer Res. 2016;76:6598-6606.
He J-Q, Sun L, He J, et al. The pathogenesis and therapeutics of nasopharyngeal carcinoma. Health Sci J. 2019;13:642.
Lo EJ, Bell D, Woo JS, et al. Human papillomavirus and WHO type I nasopharyngeal carcinoma. Laryngoscope. 2010;120:1990-1997.
Hsu W-L, Chen J-Y, Chien Y-C, et al. Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: a 20-year follow-up study on 9622 males without family history in Taiwan. Cancer Epidemiol Biomarkers Prev. 2009;18:1218-1226.